Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Identifieur interne : 001430 ( PubMed/Corpus ); précédent : 001429; suivant : 001431Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Auteurs : Adil I. Daud ; Jedd D. Wolchok ; Caroline Robert ; Wen-Jen Hwu ; Jeffrey S. Weber ; Antoni Ribas ; F Stephen Hodi ; Anthony M. Joshua ; Richard Kefford ; Peter Hersey ; Richard Joseph ; Tara C. Gangadhar ; Roxana Dronca ; Amita Patnaik ; Hassane Zarour ; Charlotte Roach ; Grant Toland ; Jared K. Lunceford ; Xiaoyun Nicole Li ; Kenneth Emancipator ; Marisa Dolled-Filhart ; S Peter Kang ; Scot Ebbinghaus ; Omid HamidSource :
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology [ 1527-7755 ] ; 2016.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized (administration & dosage), Antibodies, Monoclonal, Humanized (therapeutic use), Antigens, CD274 (metabolism), Antineoplastic Agents (administration & dosage), Antineoplastic Agents (therapeutic use), Biomarkers, Tumor (metabolism), Drug Administration Schedule, Female, Humans, Immunohistochemistry, Male, Melanoma (drug therapy), Melanoma (immunology), Melanoma (pathology), Middle Aged, Neoplasm Staging, Programmed Cell Death 1 Receptor (metabolism), Survival Rate, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Humanized, Antineoplastic Agents.
- chemical , metabolism : Antigens, CD274, Biomarkers, Tumor, Programmed Cell Death 1 Receptor.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Antineoplastic Agents.
- drug therapy : Melanoma.
- immunology : Melanoma.
- pathology : Melanoma.
- Adolescent, Adult, Aged, Aged, 80 and over, Drug Administration Schedule, Female, Humans, Immunohistochemistry, Male, Middle Aged, Neoplasm Staging, Survival Rate, Treatment Outcome.
Abstract
Purpose Expression of programmed death-ligand 1 (PD-L1) is a potential predictive marker for response and outcome after treatment with anti-programmed death 1 (PD-1). This study explored the relationship between anti-PD-1 activity and PD-L1 expression in patients with advanced melanoma who were treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clinical trial information: NCT01295827). Patients and Methods Six hundred fifty-five patients received pembrolizumab10 mg/kg once every 2 weeks or once every 3 weeks, or 2 mg/kg once every 3 weeks. Tumor response was assessed every 12 weeks per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by independent central review. Primary outcome was objective response rate. Secondary outcomes included progression-free survival (PFS) and overall survival (OS). Membranous PD-L1 expression in tumor and tumor-associated immune cells was assessed by a clinical trial immunohistochemistry assay (22C3 antibody) and scored on a unique melanoma (MEL) scale of 0 to 5 by one of three pathologists who were blinded to clinical outcome; a score ≥ 2 (membranous staining in ≥ 1% of cells) was considered positive. Results Of 451 patients with evaluable PD-L1 expression, 344 (76%) had PD-L1-positive tumors. Demographic and staging variables were equally distributed among PD-L1-positive and -negative patients. An association between higher MEL score and higher response rate and longer PFS (hazard ratio, 0.76; 95% CI, 0.71 to 0.82) and OS (hazard ratio, 0.76; 95% CI, 0.69 to 0.83) was observed ( P < .001 for each). Objective response rate was 8%, 12%, 22%, 43%, 57%, and 53% for MEL 0, 1, 2, 3, 4, and 5, respectively. Conclusion PD-L1 expression in pretreatment tumor biopsy samples was correlated with response rate, PFS, and OS; however, patients with PD-L1-negative tumors may also achieve durable responses.
DOI: 10.1200/JCO.2016.67.2477
PubMed: 27863197
Links to Exploration step
pubmed:27863197Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.</title>
<author><name sortKey="Daud, Adil I" sort="Daud, Adil I" uniqKey="Daud A" first="Adil I" last="Daud">Adil I. Daud</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wolchok, Jedd D" sort="Wolchok, Jedd D" uniqKey="Wolchok J" first="Jedd D" last="Wolchok">Jedd D. Wolchok</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hwu, Wen Jen" sort="Hwu, Wen Jen" uniqKey="Hwu W" first="Wen-Jen" last="Hwu">Wen-Jen Hwu</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Weber, Jeffrey S" sort="Weber, Jeffrey S" uniqKey="Weber J" first="Jeffrey S" last="Weber">Jeffrey S. Weber</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hodi, F Stephen" sort="Hodi, F Stephen" uniqKey="Hodi F" first="F Stephen" last="Hodi">F Stephen Hodi</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Joshua, Anthony M" sort="Joshua, Anthony M" uniqKey="Joshua A" first="Anthony M" last="Joshua">Anthony M. Joshua</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kefford, Richard" sort="Kefford, Richard" uniqKey="Kefford R" first="Richard" last="Kefford">Richard Kefford</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hersey, Peter" sort="Hersey, Peter" uniqKey="Hersey P" first="Peter" last="Hersey">Peter Hersey</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Joseph, Richard" sort="Joseph, Richard" uniqKey="Joseph R" first="Richard" last="Joseph">Richard Joseph</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gangadhar, Tara C" sort="Gangadhar, Tara C" uniqKey="Gangadhar T" first="Tara C" last="Gangadhar">Tara C. Gangadhar</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dronca, Roxana" sort="Dronca, Roxana" uniqKey="Dronca R" first="Roxana" last="Dronca">Roxana Dronca</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Patnaik, Amita" sort="Patnaik, Amita" uniqKey="Patnaik A" first="Amita" last="Patnaik">Amita Patnaik</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zarour, Hassane" sort="Zarour, Hassane" uniqKey="Zarour H" first="Hassane" last="Zarour">Hassane Zarour</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Roach, Charlotte" sort="Roach, Charlotte" uniqKey="Roach C" first="Charlotte" last="Roach">Charlotte Roach</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Toland, Grant" sort="Toland, Grant" uniqKey="Toland G" first="Grant" last="Toland">Grant Toland</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lunceford, Jared K" sort="Lunceford, Jared K" uniqKey="Lunceford J" first="Jared K" last="Lunceford">Jared K. Lunceford</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Li, Xiaoyun Nicole" sort="Li, Xiaoyun Nicole" uniqKey="Li X" first="Xiaoyun Nicole" last="Li">Xiaoyun Nicole Li</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Emancipator, Kenneth" sort="Emancipator, Kenneth" uniqKey="Emancipator K" first="Kenneth" last="Emancipator">Kenneth Emancipator</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dolled Filhart, Marisa" sort="Dolled Filhart, Marisa" uniqKey="Dolled Filhart M" first="Marisa" last="Dolled-Filhart">Marisa Dolled-Filhart</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kang, S Peter" sort="Kang, S Peter" uniqKey="Kang S" first="S Peter" last="Kang">S Peter Kang</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ebbinghaus, Scot" sort="Ebbinghaus, Scot" uniqKey="Ebbinghaus S" first="Scot" last="Ebbinghaus">Scot Ebbinghaus</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hamid, Omid" sort="Hamid, Omid" uniqKey="Hamid O" first="Omid" last="Hamid">Omid Hamid</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27863197</idno>
<idno type="pmid">27863197</idno>
<idno type="doi">10.1200/JCO.2016.67.2477</idno>
<idno type="wicri:Area/PubMed/Corpus">001430</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001430</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.</title>
<author><name sortKey="Daud, Adil I" sort="Daud, Adil I" uniqKey="Daud A" first="Adil I" last="Daud">Adil I. Daud</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wolchok, Jedd D" sort="Wolchok, Jedd D" uniqKey="Wolchok J" first="Jedd D" last="Wolchok">Jedd D. Wolchok</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hwu, Wen Jen" sort="Hwu, Wen Jen" uniqKey="Hwu W" first="Wen-Jen" last="Hwu">Wen-Jen Hwu</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Weber, Jeffrey S" sort="Weber, Jeffrey S" uniqKey="Weber J" first="Jeffrey S" last="Weber">Jeffrey S. Weber</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hodi, F Stephen" sort="Hodi, F Stephen" uniqKey="Hodi F" first="F Stephen" last="Hodi">F Stephen Hodi</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Joshua, Anthony M" sort="Joshua, Anthony M" uniqKey="Joshua A" first="Anthony M" last="Joshua">Anthony M. Joshua</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kefford, Richard" sort="Kefford, Richard" uniqKey="Kefford R" first="Richard" last="Kefford">Richard Kefford</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hersey, Peter" sort="Hersey, Peter" uniqKey="Hersey P" first="Peter" last="Hersey">Peter Hersey</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Joseph, Richard" sort="Joseph, Richard" uniqKey="Joseph R" first="Richard" last="Joseph">Richard Joseph</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gangadhar, Tara C" sort="Gangadhar, Tara C" uniqKey="Gangadhar T" first="Tara C" last="Gangadhar">Tara C. Gangadhar</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dronca, Roxana" sort="Dronca, Roxana" uniqKey="Dronca R" first="Roxana" last="Dronca">Roxana Dronca</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Patnaik, Amita" sort="Patnaik, Amita" uniqKey="Patnaik A" first="Amita" last="Patnaik">Amita Patnaik</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zarour, Hassane" sort="Zarour, Hassane" uniqKey="Zarour H" first="Hassane" last="Zarour">Hassane Zarour</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Roach, Charlotte" sort="Roach, Charlotte" uniqKey="Roach C" first="Charlotte" last="Roach">Charlotte Roach</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Toland, Grant" sort="Toland, Grant" uniqKey="Toland G" first="Grant" last="Toland">Grant Toland</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lunceford, Jared K" sort="Lunceford, Jared K" uniqKey="Lunceford J" first="Jared K" last="Lunceford">Jared K. Lunceford</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Li, Xiaoyun Nicole" sort="Li, Xiaoyun Nicole" uniqKey="Li X" first="Xiaoyun Nicole" last="Li">Xiaoyun Nicole Li</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Emancipator, Kenneth" sort="Emancipator, Kenneth" uniqKey="Emancipator K" first="Kenneth" last="Emancipator">Kenneth Emancipator</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dolled Filhart, Marisa" sort="Dolled Filhart, Marisa" uniqKey="Dolled Filhart M" first="Marisa" last="Dolled-Filhart">Marisa Dolled-Filhart</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kang, S Peter" sort="Kang, S Peter" uniqKey="Kang S" first="S Peter" last="Kang">S Peter Kang</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ebbinghaus, Scot" sort="Ebbinghaus, Scot" uniqKey="Ebbinghaus S" first="Scot" last="Ebbinghaus">Scot Ebbinghaus</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hamid, Omid" sort="Hamid, Omid" uniqKey="Hamid O" first="Omid" last="Hamid">Omid Hamid</name>
<affiliation><nlm:affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</title>
<idno type="eISSN">1527-7755</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antibodies, Monoclonal, Humanized (administration & dosage)</term>
<term>Antibodies, Monoclonal, Humanized (therapeutic use)</term>
<term>Antigens, CD274 (metabolism)</term>
<term>Antineoplastic Agents (administration & dosage)</term>
<term>Antineoplastic Agents (therapeutic use)</term>
<term>Biomarkers, Tumor (metabolism)</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Humans</term>
<term>Immunohistochemistry</term>
<term>Male</term>
<term>Melanoma (drug therapy)</term>
<term>Melanoma (immunology)</term>
<term>Melanoma (pathology)</term>
<term>Middle Aged</term>
<term>Neoplasm Staging</term>
<term>Programmed Cell Death 1 Receptor (metabolism)</term>
<term>Survival Rate</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term>
<term>Antineoplastic Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antigens, CD274</term>
<term>Biomarkers, Tumor</term>
<term>Programmed Cell Death 1 Receptor</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term>
<term>Antineoplastic Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Melanoma</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Melanoma</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Melanoma</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Humans</term>
<term>Immunohistochemistry</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neoplasm Staging</term>
<term>Survival Rate</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Purpose Expression of programmed death-ligand 1 (PD-L1) is a potential predictive marker for response and outcome after treatment with anti-programmed death 1 (PD-1). This study explored the relationship between anti-PD-1 activity and PD-L1 expression in patients with advanced melanoma who were treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clinical trial information: NCT01295827). Patients and Methods Six hundred fifty-five patients received pembrolizumab10 mg/kg once every 2 weeks or once every 3 weeks, or 2 mg/kg once every 3 weeks. Tumor response was assessed every 12 weeks per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by independent central review. Primary outcome was objective response rate. Secondary outcomes included progression-free survival (PFS) and overall survival (OS). Membranous PD-L1 expression in tumor and tumor-associated immune cells was assessed by a clinical trial immunohistochemistry assay (22C3 antibody) and scored on a unique melanoma (MEL) scale of 0 to 5 by one of three pathologists who were blinded to clinical outcome; a score ≥ 2 (membranous staining in ≥ 1% of cells) was considered positive. Results Of 451 patients with evaluable PD-L1 expression, 344 (76%) had PD-L1-positive tumors. Demographic and staging variables were equally distributed among PD-L1-positive and -negative patients. An association between higher MEL score and higher response rate and longer PFS (hazard ratio, 0.76; 95% CI, 0.71 to 0.82) and OS (hazard ratio, 0.76; 95% CI, 0.69 to 0.83) was observed ( P < .001 for each). Objective response rate was 8%, 12%, 22%, 43%, 57%, and 53% for MEL 0, 1, 2, 3, 4, and 5, respectively. Conclusion PD-L1 expression in pretreatment tumor biopsy samples was correlated with response rate, PFS, and OS; however, patients with PD-L1-negative tumors may also achieve durable responses.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27863197</PMID>
<DateCreated><Year>2016</Year>
<Month>11</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted><Year>2017</Year>
<Month>07</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>11</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-7755</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>34</Volume>
<Issue>34</Issue>
<PubDate><Year>2016</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title>
<ISOAbbreviation>J. Clin. Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.</ArticleTitle>
<Pagination><MedlinePgn>4102-4109</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Purpose Expression of programmed death-ligand 1 (PD-L1) is a potential predictive marker for response and outcome after treatment with anti-programmed death 1 (PD-1). This study explored the relationship between anti-PD-1 activity and PD-L1 expression in patients with advanced melanoma who were treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clinical trial information: NCT01295827). Patients and Methods Six hundred fifty-five patients received pembrolizumab10 mg/kg once every 2 weeks or once every 3 weeks, or 2 mg/kg once every 3 weeks. Tumor response was assessed every 12 weeks per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by independent central review. Primary outcome was objective response rate. Secondary outcomes included progression-free survival (PFS) and overall survival (OS). Membranous PD-L1 expression in tumor and tumor-associated immune cells was assessed by a clinical trial immunohistochemistry assay (22C3 antibody) and scored on a unique melanoma (MEL) scale of 0 to 5 by one of three pathologists who were blinded to clinical outcome; a score ≥ 2 (membranous staining in ≥ 1% of cells) was considered positive. Results Of 451 patients with evaluable PD-L1 expression, 344 (76%) had PD-L1-positive tumors. Demographic and staging variables were equally distributed among PD-L1-positive and -negative patients. An association between higher MEL score and higher response rate and longer PFS (hazard ratio, 0.76; 95% CI, 0.71 to 0.82) and OS (hazard ratio, 0.76; 95% CI, 0.69 to 0.83) was observed ( P < .001 for each). Objective response rate was 8%, 12%, 22%, 43%, 57%, and 53% for MEL 0, 1, 2, 3, 4, and 5, respectively. Conclusion PD-L1 expression in pretreatment tumor biopsy samples was correlated with response rate, PFS, and OS; however, patients with PD-L1-negative tumors may also achieve durable responses.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Daud</LastName>
<ForeName>Adil I</ForeName>
<Initials>AI</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wolchok</LastName>
<ForeName>Jedd D</ForeName>
<Initials>JD</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Robert</LastName>
<ForeName>Caroline</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hwu</LastName>
<ForeName>Wen-Jen</ForeName>
<Initials>WJ</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Weber</LastName>
<ForeName>Jeffrey S</ForeName>
<Initials>JS</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ribas</LastName>
<ForeName>Antoni</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hodi</LastName>
<ForeName>F Stephen</ForeName>
<Initials>FS</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Joshua</LastName>
<ForeName>Anthony M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kefford</LastName>
<ForeName>Richard</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hersey</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Joseph</LastName>
<ForeName>Richard</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gangadhar</LastName>
<ForeName>Tara C</ForeName>
<Initials>TC</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dronca</LastName>
<ForeName>Roxana</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Patnaik</LastName>
<ForeName>Amita</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zarour</LastName>
<ForeName>Hassane</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Roach</LastName>
<ForeName>Charlotte</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Toland</LastName>
<ForeName>Grant</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lunceford</LastName>
<ForeName>Jared K</ForeName>
<Initials>JK</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Xiaoyun Nicole</ForeName>
<Initials>XN</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Emancipator</LastName>
<ForeName>Kenneth</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dolled-Filhart</LastName>
<ForeName>Marisa</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kang</LastName>
<ForeName>S Peter</ForeName>
<Initials>SP</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ebbinghaus</LastName>
<ForeName>Scot</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hamid</LastName>
<ForeName>Omid</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P30 CA015083</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>10</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Clin Oncol</MedlineTA>
<NlmUniqueID>8309333</NlmUniqueID>
<ISSNLinking>0732-183X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D060890">Antigens, CD274</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>DPT0O3T46P</RegistryNumber>
<NameOfSubstance UI="C582435">pembrolizumab</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Nature. 2014 Nov 27;515(7528):563-7</RefSource>
<PMID Version="1">25428504</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int Immunol. 1996 May;8(5):765-72</RefSource>
<PMID Version="1">8671665</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>EMBO J. 1992 Nov;11(11):3887-95</RefSource>
<PMID Version="1">1396582</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2010 Jul 1;28(19):3167-75</RefSource>
<PMID Version="1">20516446</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nature. 2014 Nov 27;515(7528):568-71</RefSource>
<PMID Version="1">25428505</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 2016 Apr 19;315 (15):1600-9</RefSource>
<PMID Version="1">27092830</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2014 Sep 20;384(9948):1109-17</RefSource>
<PMID Version="1">25034862</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Jun 28;366(26):2443-54</RefSource>
<PMID Version="1">22658127</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 1995 Aug 1;182(2):459-65</RefSource>
<PMID Version="1">7543139</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2009 Dec 1;15(23 ):7412-20</RefSource>
<PMID Version="1">19934295</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Science. 2011 Mar 25;331(6024):1565-70</RefSource>
<PMID Version="1">21436444</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2016 Jun;17 (6):717-726</RefSource>
<PMID Version="1">27157491</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2016 Jun 27;:null</RefSource>
<PMID Version="1">27354476</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2016 Sep 19;:null</RefSource>
<PMID Version="1">27646946</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Rev Cancer. 2012 Mar 22;12(4):252-64</RefSource>
<PMID Version="1">22437870</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Aug 19;363(8):711-23</RefSource>
<PMID Version="1">20525992</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Immunol. 2003 Oct;33(10):2706-16</RefSource>
<PMID Version="1">14515254</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 Jul 11;369(2):134-44</RefSource>
<PMID Version="1">23724846</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Jan 22;372(4):320-30</RefSource>
<PMID Version="1">25399552</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Jun 30;364(26):2517-26</RefSource>
<PMID Version="1">21639810</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Annu Rev Med. 2014;65:185-202</RefSource>
<PMID Version="1">24188664</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2009 Jan;45(2):228-47</RefSource>
<PMID Version="1">19097774</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mod Pathol. 1998 Feb;11(2):155-68</RefSource>
<PMID Version="1">9504686</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Jun 25;372(26):2521-32</RefSource>
<PMID Version="1">25891173</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 2000 Oct 2;192(7):1027-34</RefSource>
<PMID Version="1">11015443</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Stat Med. 1985 Apr-Jun;4(2):213-26</RefSource>
<PMID Version="1">4023479</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2015 Aug;16(8):908-18</RefSource>
<PMID Version="1">26115796</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2016 Jul 20;34(21):2460-7</RefSource>
<PMID Version="1">27138582</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 May 21;372(21):2018-28</RefSource>
<PMID Version="1">25891174</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Thorac Oncol. 2015 Jul;10(7):985-9</RefSource>
<PMID Version="1">26134220</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Immunity. 2013 Jul 25;39(1):1-10</RefSource>
<PMID Version="1">23890059</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pigment Cell Melanoma Res. 2015 May;28(3):245-53</RefSource>
<PMID Version="1">25477049</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Jul 2;373(1):23-34</RefSource>
<PMID Version="1">26027431</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Sci Transl Med. 2012 Mar 28;4(127):127ra37</RefSource>
<PMID Version="1">22461641</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Blood. 2007 Jul 1;110(1):296-304</RefSource>
<PMID Version="1">17363736</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Cancer. 2014 Jan 24;5(3):166-72</RefSource>
<PMID Version="1">24563671</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D060890" MajorTopicYN="N">Antigens, CD274</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>11</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>11</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>7</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27863197</ArticleId>
<ArticleId IdType="pii">10.1200/JCO.2016.67.2477</ArticleId>
<ArticleId IdType="doi">10.1200/JCO.2016.67.2477</ArticleId>
<ArticleId IdType="pmc">PMC5562434</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001430 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001430 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:27863197 |texte= Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27863197" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |